TenNor Therapeutics Funding: $109M Raised, Series B (2016)
TenNor Therapeutics is based in Suzhou, China. It has raised $109M in total funding. Latest round: Series B.
TenNor Therapeutics funding overview
TenNor Therapeutics is based in Suzhou, China. TenNor Therapeutics has raised $109M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series B announced in September 2016. The round record for TenNor Therapeutics runs through 2016; nothing later has been disclosed. Investors on record include Northern Light Venture Capital, Frontline BioVentures, WuXi PharmaTech Healthcare Fund I, Oriza Venture Capital, Relativity Healthcare Fund. 5 distinct backers are named across the disclosed rounds.
TenNor Therapeutics at a glance
Total raised
$109M
Latest round
Series B
Latest round date
September 2016
Headquarters
Suzhou, China
Notable investors
Northern Light Venture Capital, Frontline BioVentures, WuXi PharmaTech Healthcare Fund I, Oriza Venture Capital, Relativity Healthcare Fund
Frequently asked about TenNor Therapeutics funding
How much has TenNor Therapeutics raised?
TenNor Therapeutics has raised $109M in total disclosed funding across the rounds on record.
Who has invested in TenNor Therapeutics?
Northern Light Venture Capital, Frontline BioVentures, WuXi PharmaTech Healthcare Fund I, Oriza Venture Capital, Relativity Healthcare Fund are named among the investors backing TenNor Therapeutics.
What was the latest TenNor Therapeutics funding round?
The most recent disclosed round is a Series B, announced in September 2016.
Where is TenNor Therapeutics based?
TenNor Therapeutics is based in Suzhou, China.
When did TenNor Therapeutics last raise?
The last disclosed TenNor Therapeutics round closed in September 2016 at Series B.
Round data for TenNor Therapeutics is compiled from public filings and announcements; blank fields mean nothing has been disclosed rather than nothing exists. Continue with the companies in Suzhou and backer lists below.
